Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9HCJ5
UPID:
ZSWM6_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HCJ5
Background:
Zinc finger SWIM domain-containing protein 6 plays a pivotal role in nervous system development, particularly influencing striatal morphology and motor regulation. This protein's involvement in key developmental pathways underscores its importance in cellular function and organismal development.
Therapeutic significance:
Given its crucial role in nervous system development and association with Acromelic frontonasal dysostosis and a neurodevelopmental disorder with movement abnormalities and autistic features, targeting Zinc finger SWIM domain-containing protein 6 could lead to novel treatments for these conditions.